Sensorion

Report Publication Announcement • Feb 8, 2016

Sensorion Provides 2016 Financial Calendar

Montpellier, France, February 8, 2016 – Sensorion (FR0012596468 – ALSEN), a biotech company specializing in the treatment of inner ear diseases, today published its financial calendar for 2016.

Event	Date*
2015 Full-Year Results	Thursday, March 17, 2016
Shareholders' Meeting	Friday, April 29, 2016
2016 Half-Year Results	Monday, October 31, 2016

In addition to these periodic announcements, investors can consult the Company's website (www.sensorion-pharma.com) where information is updated on a regular basis. All corporate and financial information on the Company is available on it's website in the Investors section.

●●●

* Dates of the company's scheduled announcements are subject to change.

About Sensorion

Sensorion specializes in the treatment of pathologies of the inner ear such as acute vertigo, tinnitus and hearing loss. The company was founded by Inserm (the French Institute of Health and Medical Research) and is utilizing its pharmaceutical R&D experience and comprehensive technology platform to develop three drug candidate programs for treating the symptoms of vertigo and tinnitus, for preventing complications associated with progressive lesions in the inner ear, and for preventing the toxicity of chemotherapy in the inner ear. Based in Montpellier, southern France, Sensorion has a portfolio of 7 patent families, employs 16 staff and receives financial support from Bpifrance, through the InnoBio fund, and Inserm Transfert Initiative. Sensorion is listed on Alternext Paris since April 2015. www.sensorion-pharma.com

Contacts

Sensorion Laurent Nguyen CEO contact@sensorion-pharma.com Tel: +33 (0)4 67 20 77 30

Name: SENSORION ISIN code: FR0012596468 Ticker: ALSEN

International Investor Relations NewCap Dusan Oresansky / Emmanuel Huynh sensorion@newcap.eu Tel: +33 (0)1 44 71 94 92

US Investor Relations The Ruth Group David Burke dburke@theruthgroup.com Tel: +1 (646) 536 7009